RUDZANOVÁ, Barbora, Jelle VLAANDEREN, Jiří KALINA, Pavel PILER, Martin ZVONAŘ, Jana KLÁNOVÁ, Luděk BLÁHA and Ondřej ADAMOVSKÝ. Impact of PFAS exposure on prevalence of immune-mediated diseases in adults in the Czech Republic. Environmental Research. Elsevier, 2023, vol. 229, July 2023, p. 1-12. ISSN 0013-9351. Available from: https://dx.doi.org/10.1016/j.envres.2023.115969.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Impact of PFAS exposure on prevalence of immune-mediated diseases in adults in the Czech Republic
Authors RUDZANOVÁ, Barbora (203 Czech Republic, belonging to the institution), Jelle VLAANDEREN, Jiří KALINA (203 Czech Republic, belonging to the institution), Pavel PILER (203 Czech Republic, belonging to the institution), Martin ZVONAŘ (203 Czech Republic, belonging to the institution), Jana KLÁNOVÁ (203 Czech Republic, belonging to the institution), Luděk BLÁHA (203 Czech Republic, belonging to the institution) and Ondřej ADAMOVSKÝ (203 Czech Republic, guarantor, belonging to the institution).
Edition Environmental Research, Elsevier, 2023, 0013-9351.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10511 Environmental sciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 8.300 in 2022
RIV identification code RIV/00216224:14310/23:00131221
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1016/j.envres.2023.115969
UT WoS 000992616900001
Keywords in English Perfluoroalkyl substances; Immune system; Adult cohort; Allergy; Eczema; Bayesian kernel machine regression
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Michaela Hylsová, Ph.D., učo 211937. Changed: 8/3/2024 22:14.
Abstract
Background: Per-and polyfluoroalkyl substances (PFASs) are emerging environmental contaminants with mul-tiple hazardous properties including immunomodulation potency. Human exposure to PFASs has been associated with various immune-mediated diseases and outcomes. This study aimed to investigate the association between PFAS exposure and immune-mediated diseases such as allergies, eczemas, and autoimmune diseases in a pop-ulation of adults in the Czech Republic.Methods: This study included 309 adults from the Central European Longitudinal Study of Parents and Children: Young Adults (CELSPAC: YA). 12 PFASs were measured in participants' serum by HPLC-MS/MS, 3 PFASs were removed from the subsequent analyses due to low detection frequency. The associations of 9 PFASs with 9 immune-mediated diseases were assessed by logistic regression. Furthermore, Bayesian kernel machine regres-sion (BKMR) was used to estimate the effect of the PFAS mixture on immune-mediated diseases. All analyses were adjusted for sex, age, BMI, smoking, education, and family history of immune-mediated diseases. In cases of a statistically significant interaction of PFASs and sex, stratified analyses were performed for men and women.Results: Perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) were negatively associated with both atopic eczema (OR per IQR increase 0.58 (95% CI 0.37-0.90) for PFOA and 0.56 (0.32-0.95) for PFOS) and contact dermatitis (0.37 (0.16-0.85) for PFOA and 0.33 (0.11-0.94) for PFOS). Perfluoroundecanoate (PFUnDA) was negatively associated with pollen, dust, and mite allergy (0.62 (0.43-0.89)). BKMR modelling showed a negative tendency in the overall effect of PFAS mixture on immune-health outcomes. Based on the stratified analysis, sex was suggested to be an effect modifier in the association of PFOS and atopic eczema.Conclusion: Our results contribute to the body of literature that observes the immunosuppressive effect of PFAS exposure during eczemas and allergies, both for PFASs individually and as a mixture.
Links
EF15_003/0000469, research and development projectName: Cetocoen Plus
EF17_043/0009632, research and development projectName: CETOCOEN Excellence
857560, interní kód MU
(CEP code: EF17_043/0009632)
Name: CETOCOEN Excellence (Acronym: CETOCOEN Excellence)
Investor: European Union, Spreading excellence and widening participation
90121, large research infrastructuresName: RECETOX RI
PrintDisplayed: 18/7/2024 23:31